Structural Chromosomal Alterations Induced by Dietary Bioflavonoids in Fanconi Anemia Lymphocytes

Introduction Fanconi anemia is an autosomal recessive disease characterized by a variety of congenital abnormalities, progressive bone marrow failure, increased chromosomal instability and higher risk to acute myeloid leukemia, solid tumors. This entity can be considered an appropriate biological model to analyze natural substances with possible genotoxic effect. The aims of this study were to describe and quantify structural chromosomal aberrations induced by 5 flavones, 2 isoflavones and a topoisomerase II chemotherapeutic inhibitor in Fanconi anemia lymphocytes in order to determine chromosomal numbers changes and/ or type of chromosomal damage. Materials and methods Chromosomes stimulated by phytohaemagglutinin M, from Fanconi anemia lymphocytes, were analysed by conventional cytogenetic culture. For each chemical substance and controls, one hundred metaphases were evaluated. Chromosomal alterations were documented by photography and imaging analyzer. To statistical analysis was used chi square test to identify significant differences between frequencies of chromosomal damage of basal and exposed cell cultured a P value less than 0.05. Results There were 431 chromosomal alterations in 1000 metaphases analysed; genistein was the more genotoxic bioflavonoid, followed in descendent order by genistin, fisetin, kaempferol, quercetin, baicalein and miricetin. Chromosomal aberrations observed were: chromatid breaks, chromosomal breaks, cromatid and chromosomal gaps, quadriratials exchanges, dicentrics chromosome and complex rearrangements. Conclusion Bioflavonoids as genistein, genistin and fisetin, which are commonly present in the human diet, showed statistical significance in the number of chromosomal aberrations in Fanconi anemia lymphocytes, regarding the basal damage.

Asociación entre psoriasis y el control de diabetes mellitus tipo 2

La psoriasis es una enfermedad que se caracteriza por un proceso inflamatorio crónico y exagerado local y sistémico. Se ha encontrado en la literatura una relación entre la psoriasis y el desarrollo de patologías como diabetes mellitus tipo 2 y el mal control de estas patologías, lo cual aumenta la morbimortalidad de estos pacientes. El presente estudio mostró que no se encontró asociación entre psoriasis y el control de la DM2 , y que la variable mas significativa sobre el control es la adherencia al tratamiento hipoglicemiante.

Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?

The present study aimed to assess the tolerance and efficacy of rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 receptor present in B lymphocytes, in patients with autoimmune rheumatic diseases (AIRD). For this purpose, patients treated with RTX and their respective clinical charts were comprehensively examined. Indications for treatment were a refractory character of the disease, inefficacy or intolerance of other immunosuppressors. Activity indexes (SLEDAI, DAS28, and specific clinical manifestations) were used to evaluate efficacy. Serious side effects were also recorded. Seventy-four patients were included. Forty-three patients had systemic lupus erythematosus (SLE), 21 had rheumatoid arthritis (RA), 8 had Sjögren’s syndrome (SS), and 2 had Takayasu’s arteritis (TA). RTX was well-tolerated in 66 (89%) patients. In 8 patients (SLE = 3, SS = 3, RA = 2), serious side effects lead to discontinuation. The mean follow-up period was 12 ± 7.8 (2–35) months. The efficacy of RTX was registered in 58/66 (87%) patients, of whom 36 (83%) had SLE, 18/21 (85%) had RA, 3/8 (37%) had SS, and 1 had TA. The mean time of efficacy was 6.3 ± 5.1 weeks. A significant steroid-sparing effect was noticed in half of the patients. These results add further evidence for the use of RTX in AIRD. Based on its risk–benefit ratio, RTX might be used as the first-choice treatment for patients with severe AIRD.

Linfocitos atípicos en dengue: papel en el diagnóstico y pronóstico de la enfermedad. Revisión sistemática de la literatura

El dengue es la arbovirosis de mayor incidencia mundial y una importante causa de morbilidad y mortalidad. Debido a que la enfermedad se presenta en principio como un cuadro febril inespecífico, se requieren herramientas que permitan reconocer y clasificar a los pacientes con dengue en forma temprana. Un parámetro de utilidad en este sentido puede ser la presencia de linfocitos atípicos. Objetivo: revisar los resultados de los trabajos originales existentes en la literatura sobre linfocitos atípicos e infección por virus dengue y su papel en el diagnóstico y pronóstico de la enfermedad. Materiales y métodos: para la revisión se emplearon los motores de búsqueda PubMed y Lilacs, bajo la combinación de términos Dengue AND Atypical lymphocyte (OR Reactive lymphocyte, OR Turk cell), limitando los hallazgos a estudios en humanos. La información obtenidafue clasificada por su contenido. Solo se incluyeron en el presente trabajo los estudios relevantes para el tema. Resultados: se ajustaron 68 referencias a la estrategia de búsqueda empleada, pero solo doce correspondían al objeto de la revisión. Todos los estudios incluidos reportaron presenciade linfocitos atípicos como hallazgo hematológico particular en pacientes con dengue y aunque no fue un hallazgo específico de la enfermedad, su concentración fue significativamente superioren estos pacientes, sobre todo en cuadros severos de la misma. Conclusiones: de acuerdo con la evidencia encontrada, puede considerarse que existe una asociación entre la presencia de linfocitos atípicos y la infección por el virus dengue; sin embargo, la intensidad y utilidad de este hallazgo requiere mayor estudio y análisis.